<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412022000300007</article-id>
<article-id pub-id-type="doi">10.24245/gom.v90i3.7317</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tumor limítrofe del ovario: revisión de un viejo conocido con nuevas propuestas terapéuticas]]></article-title>
<article-title xml:lang="en"><![CDATA[Ovarian borderline tumor: Review of an old acquaintance with new therapeutic proposals]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Novoa-Vargas]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Contreras-Álvarez]]></surname>
<given-names><![CDATA[Judith]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Escorcia]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Juárez servicio de Anatomía Patológica ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>90</volume>
<numero>3</numero>
<fpage>261</fpage>
<lpage>272</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412022000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  Las pacientes con un tumor limítrofe del ovario pueden tratarse conservadoramente en etapas tempranas y con ello conseguir una supervivencia considerable. Las etapas avanzadas tienen un periodo libre de enfermedad prolongado, algunas con crecimiento de implantes peritoneales y recaída posterior a 10 años del tratamiento.  OBJETIVO:  Conocer cuál es el pronóstico de las pacientes con un tumor limítrofe del ovario, y su tratamiento en México y otros países.  MÉTODOLOGÍA:  Revisión sistemática de ensayos clínicos recientes registrados en las bases de datos de PubMed, Embase y Cochrane de artículos publicados en inglés y en español entre los años 2006 y 2021. Además, una revisión analítica de la experiencia acumulada en 10 años en la atención de pacientes con tumor limítrofe del ovario atendidas en la Unidad Médica de Alta Especialidad de Oncología del Centro Médico Nacional siglo XXI del Instituto Mexicano del Seguro Social, en la Ciudad de México y otros centros médicos de la República Mexicana.  RESULTADOS:  Se encontraron 62 artículos relacionados con los términos de búsqueda; de éstos, se descartaron 11 porque no eran artículos originales solo de tumores limítrofes del ovario y 4 porque el texto completo estaba escrito en idiomas diferentes al inglés y español. Uno más se eliminó porque sus conclusiones diferían del objetivo planteado y su sustento se consideró endeble. Al final se analizaron 41 artículos.  CONCLUSIONES:  Las posibilidades de atención quirúrgica de pacientes con tumor limítrofe del ovario, con preservación de la fertilidad, son altas pues su recurrencia es baja. Los tumores microinvasores mucinosos, con permeación vascular y linfática, tendrán mayor posibilidad de recaída a largo plazo. En general, su pronóstico de supervivencia, en cada etapa, es alto. La linfadenectomía retroperitoneal no está indicada en etapas tempranas de la enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  Patients with borderline ovarian tumor can be treated conservatively in early stages and thereby achieve considerable survival. Advanced stages have a prolonged disease-free period, some with peritoneal implant growth and relapse after 10 years of treatment.  OBJECTIVE:  To know the prognosis of patients with borderline ovarian tumor and its treatment in Mexico and other countries.  METHODOLOGY:  Systematic review of recent clinical trials registered in PubMed, Embase and Cochrane databases of articles published in English and Spanish between 2006 and 2021. In addition, an analytical review of the experience accumulated in 10 years in the care of patients with borderline ovarian tumor attended at the Oncology High Specialty Medical Unit of the XXI Century National Medical Center of the Mexican Social Security Institute, in Mexico City and other medical centers in the Mexican Republic.  RESULTS:  We found 62 articles related to the search terms; of these, 11 were discarded because they were not original articles only on ovarian borderline tumors and 4 because the full text was written in languages other than English and Spanish. One more was eliminated because its conclusions differed from the stated objective and its support was considered weak. In the end, 41 articles were analyzed.  CONCLUSIONS:  The chances of surgical care of patients with ovarian borderline tumor, with fertility preservation, are high because its recurrence is low. Mucinous microinvasive tumors, with vascular and lymphatic permeation, will have a higher chance of long-term relapse. In general, their prognosis for survival, at each stage, is high. Retroperitoneal lymphadenectomy is not indicated in early stages of the disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tumor limítrofe del ovario]]></kwd>
<kwd lng="es"><![CDATA[tumor de ovario]]></kwd>
<kwd lng="es"><![CDATA[neoplasias del ovario]]></kwd>
<kwd lng="es"><![CDATA[prese preservación de la fertilidad]]></kwd>
<kwd lng="es"><![CDATA[escisión de ganglios linfáticos]]></kwd>
<kwd lng="es"><![CDATA[linfadenectomía]]></kwd>
<kwd lng="es"><![CDATA[recurrencia de neoplasias, local]]></kwd>
<kwd lng="es"><![CDATA[estadificación de neoplasias]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="es"><![CDATA[Seguridad Social]]></kwd>
<kwd lng="en"><![CDATA[Ovarian borderline tumor]]></kwd>
<kwd lng="en"><![CDATA[Ovarian tumor]]></kwd>
<kwd lng="en"><![CDATA[Ovarian neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Fertility preservation]]></kwd>
<kwd lng="en"><![CDATA[Lymph node excision]]></kwd>
<kwd lng="en"><![CDATA[Lymphadenectomy]]></kwd>
<kwd lng="en"><![CDATA[Neoplasm recurrence, Local]]></kwd>
<kwd lng="en"><![CDATA[neoplasm staging]]></kwd>
<kwd lng="en"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Social Security]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant and semimalignant tumors of the ovary]]></article-title>
<source><![CDATA[Surg Gynecol Obstet]]></source>
<year>1929</year>
<volume>48</volume>
<page-range>204-30</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>International Federation of Gynecology and Obstetrics</collab>
<article-title xml:lang=""><![CDATA[Classification and staging of malignant tumors in the female pelvis]]></article-title>
<source><![CDATA[Acta Obstet Gynecol Scand]]></source>
<year>1971</year>
<volume>50</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kleppe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bruls]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Van Gorp]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucinous borderline tumours of the ovary and the appendix: A retrospective study and overview of the literature]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2014</year>
<volume>133</volume>
<page-range>155-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kavak Comert]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ureyen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alper]]></surname>
<given-names><![CDATA[Karalok]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucinous borderline ovarian tumors Analysis of 75 patients from a single center]]></article-title>
<source><![CDATA[J Turk Ger Gynecol Assoc]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>96-100</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Borderline and invasive epithelial ovarian tumors in young women]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>1993</year>
<volume>82</volume>
<page-range>752</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zapardiel]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rosednberg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Peiretti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zanagnolo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sanguineti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Aletti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of restaging borderline ovarian tumors: Single experience and review of the literature]]></article-title>
<source><![CDATA[Gynecol Onco]]></source>
<year>2010</year>
<volume>119</volume>
<page-range>274-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres-Lobatón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan-Ortiz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumores limítrofes de ovario, experiencia de 50 casos]]></article-title>
<source><![CDATA[GAMO]]></source>
<year>2016</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>70-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gershenson]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical management potential tumours of low malignancy]]></article-title>
<source><![CDATA[Best Pract Res Clin Obstet Gynaecol]]></source>
<year>2002</year>
<volume>16</volume>
<page-range>513-27</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosbell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carcangui]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sero-mucinosus tumours]]></article-title>
<source><![CDATA[WHO Classification IARC]]></source>
<year>2014</year>
<page-range>38-40</page-range><publisher-loc><![CDATA[Lyon ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis and the role of ARIDIA mutation in endometriosis-related ovarian neoplasms Adv. Anat]]></article-title>
<source><![CDATA[Pathol]]></source>
<year>2013</year>
<volume>20</volume>
<page-range>45-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Disaia]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncologia Ginecológica Clínica en Tumores anexiales]]></article-title>
<source><![CDATA[Elsevier,]]></source>
<year>2018</year>
<page-range>245-52</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis]]></article-title>
<source><![CDATA[Ann Lab Med]]></source>
<year>2020</year>
<volume>40</volume>
<page-range>40-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Steady, relentless progress towards effective, safe screening for early detection of cancer of the ovary]]></article-title>
<source><![CDATA[BJOG]]></source>
<year>2018</year>
<volume>125</volume>
<page-range>526-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cömert]]></surname>
<given-names><![CDATA[Kavak]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analyzing of mBOTs]]></article-title>
<source><![CDATA[J Turk Ger Gynecol Assoc]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>96-10</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qing]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and computed tomographic features of ovarian lesions in infants, children, and adolescents: A series of 222 cases]]></article-title>
<source><![CDATA[Pediatr Adolesc Gynecol]]></source>
<year>2021</year>
<numero>34</numero>
<issue>34</issue>
<page-range>387-93</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathologic features and risk factors for recurrence of mucinous borderline ovarian tumors A retrospective study with follow-up of more than 10 years]]></article-title>
<source><![CDATA[International J of Gynecological Cancer]]></source>
<year>2018</year>
<volume>28</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1643-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nyangoh]]></surname>
<given-names><![CDATA[Krystel]]></given-names>
</name>
<name>
<surname><![CDATA[Bendifallah]]></surname>
<given-names><![CDATA[Sofiane]]></given-names>
</name>
<name>
<surname><![CDATA[Lobna]]></surname>
<given-names><![CDATA[Dion]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gynecolgie Obstetrique Fertilié and]]></article-title>
<source><![CDATA[Sénologie]]></source>
<year>2020</year>
<volume>01</volume>
<page-range>23-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsilidis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Key]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dossus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lukanova]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bakken]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2011</year>
<volume>105</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1436-42</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Lander]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Venez Oncol]]></source>
<year>2014</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>235-92</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[William]]></given-names>
</name>
</person-group>
<source><![CDATA[Modern Pathology]]></source>
<year>2005</year>
<numero>18</numero>
<issue>18</issue>
<page-range>S33-50</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<source><![CDATA[JNCCN.org]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rui-fang]]></surname>
<given-names><![CDATA[Chen]]></given-names>
</name>
<name>
<surname><![CDATA[Jun]]></surname>
<given-names><![CDATA[Li]]></given-names>
</name>
<name>
<surname><![CDATA[Ting-ting]]></surname>
<given-names><![CDATA[Zhu]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fertility-sparing surgery for young patients with borderline ovarian tumors (BOT´s): single institution experience]]></article-title>
<source><![CDATA[J Ovarian Res]]></source>
<year>2016</year>
<volume>9</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2-8</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gershenson]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of borderline ovarian tumours]]></article-title>
<source><![CDATA[Obstetrics and Gyneacology]]></source>
<year>2017</year>
<volume>41</volume>
<page-range>49-59</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelovac]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent progress in the diagnosis and treatment of ovarian cancer]]></article-title>
<source><![CDATA[A Cancer J Clin]]></source>
<year>2011</year>
<volume>61</volume>
<page-range>183-203</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Della Pepa]]></given-names>
</name>
<name>
<surname><![CDATA[Tonini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Santini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low grade serous ovarian carcinoma: From the molecular characterization to the best therapeutic strategy]]></article-title>
<source><![CDATA[Cancer Treatment Rev]]></source>
<year>2015</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>136-43</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malpica A]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The molecular pathology of ovarian serous borderline tumors]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2016</year>
<numero>^sSuppl 27</numero>
<issue>^sSuppl 27</issue>
<supplement>Suppl 27</supplement>
<page-range>i16-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Lander]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loreta-Di-Giampietro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primer consenso nacional de cáncer epitelial de ovario diagnóstico y tratamiento]]></article-title>
<source><![CDATA[Rev Venez Oncol]]></source>
<year>2014</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>235-92</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schorge]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Modesitt]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Kauff]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Duska]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGO White paper on ovarian cancer Etiology, screening and surveillance]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2010</year>
<volume>119</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-17</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohnishi]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakayama]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ishikawa]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas]]></article-title>
<source><![CDATA[Arch Gynecol Obstet]]></source>
<year>2020</year>
<volume>302</volume>
<page-range>487-95</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun Li]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Int J Gynecol]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2018</year>
<volume>28</volume>
<page-range>1643-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giorgini]]></surname>
<given-names><![CDATA[Margherita]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Limits of 18F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor]]></article-title>
<source><![CDATA[Int J Gynecol Cancer]]></source>
<year>2010</year>
<volume>20</volume>
<page-range>694-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camarillo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Quezada]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<source><![CDATA[Incidencia de metástasis ganglionares en tumores de ovario limítrofes en el H de Oncología CMN, Siglo XXI]]></source>
<year>2016</year>
<publisher-name><![CDATA[IMSS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallardo-Rincón]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cantú de León]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alanís-López]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[GAMO]]></source>
<year>2011</year>
<volume>63</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>665-701</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russell Vang]]></surname>
<given-names><![CDATA[Charlotte]]></given-names>
</name>
<name>
<surname><![CDATA[G]]></surname>
<given-names><![CDATA[Hannibal]]></given-names>
</name>
<name>
<surname><![CDATA[Junge]]></surname>
<given-names><![CDATA[Jette]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Am J Surg]]></article-title>
<source><![CDATA[Pathol]]></source>
<year>2017</year>
<volume>41</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>725-37</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKenney]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Balzer]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Longacre]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los Patrones de invasión estromal en tumores serosos ováricos de bajo potencial maligno (tumores límite) una reevaluación del concepto de microinvasión estromal. J Surg Pathol]]></article-title>
<source><![CDATA[Octubre de]]></source>
<year>2006</year>
<volume>30</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1209-21</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarita]]></surname>
<given-names><![CDATA[Kumari]]></given-names>
</name>
<name>
<surname><![CDATA[Sunesh]]></surname>
<given-names><![CDATA[Kumar]]></given-names>
</name>
<name>
<surname><![CDATA[Neerja]]></surname>
<given-names><![CDATA[Bhatla]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population]]></article-title>
<source><![CDATA[Gynecol Oncol reports]]></source>
<year>2021</year>
<numero>36</numero>
<issue>36</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<collab>Shih Ie-Ming y Kurman Robert J</collab>
<article-title xml:lang=""><![CDATA[Clin Cancer]]></article-title>
<source><![CDATA[Res]]></source>
<year>2005</year>
<volume>11</volume>
<page-range>7273-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debora]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Amstrong Alvarez]]></surname>
<given-names><![CDATA[Ronal D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NCCN Clinical practice guidelines in]]></article-title>
<source><![CDATA[Oncology]]></source>
<year>2021</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-226</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hannibal]]></surname>
<given-names><![CDATA[Gerd]]></given-names>
</name>
<name>
<surname><![CDATA[Kjaer]]></surname>
<given-names><![CDATA[Susanne K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Nationwide Study of Ovarian Serous Borderline Tumors in Denmark 1978-2002 Risk of Recurrence, and Development of Ovarian Serous Carcinoma]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2017</year>
<volume>144</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>174-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
